article = {COR-2019-5-104}
title = {Budosenid Treatment of Avelumab Induced Autoimmune Colitis in Patient With Metastatic Merkel Cell Carcinoma; A Case Report}
journal = {Clinical Oncology and Research}
year = {2019}
issn = {2613-4942}
doi = {http://dx.doi.org/10.31487/j.COR.2019.05.04}
url = {https://www.sciencerepository.org/budosenid-treatment-of-avelumab-induced-autoimmune-colitis-in-patient-with-metastatic-merkel-cell-carcinoma_COR-2019-5-104 
author = {El Ali Ziad,Verset Laurine,}
keywords = {Oral budesonid, avelumab, autoimmune colitis}
abstract ={Merkel cell carcinoma is a rare and highly agressive primary cutaneous cancer with epithelial and neuroendocrine features. Currently, for stage IV disease, up-front immunotherapy with check-point inhibitors, anti PD-L1 and anti PD-1, is recommanded. We report the case of a patient who was treated with Avelumab for a metastatic Merkel cell carcinoma. He presented a treatment induced grade II immune colitis, treated successfully with oral Budesonid, a synthetic steroid with high topical anti-inflammatory activity, minimal systemic absorption, and fewer side effects.  }